Evidence map›Paper›PMID 39103897›Full record

ArticleJournal of translational medicine2024

Integrating knowledge graphs into machine learning models for survival prediction and biomarker discovery in patients with non-small-cell lung cancer.

Chao Fang, Gustavo Alonso Arango Argoty, Ioannis Kagiampakis, Mohammad Hassan Khalid, Etai Jacob, Krishna C Bulusu, Natasha Markuzon

2 registry-linked trialsAbstract read
In one paragraph

Article in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01903993 phase2completednot on this map

A Phase II, Open-label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Platinum Failure

TypeinterventionalSponsorHoffmann-La RocheRan2013 to 2018Enrolled287ConditionsNon-Small Cell Lung CancerArmsDocetaxel, Atezolizumab
NCT02008227 phase3completednot on this map

A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy

TypeinterventionalSponsorHoffmann-La RocheRan2014 to 2019Enrolled1,225ConditionsNon-Squamous Non-Small Cell Lung CancerArmsAtezolizumab, Docetaxel
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chao FangOncology Data Science, Oncology R&D, AstraZeneca, Waltham, MA, USA.
Gustavo Alonso Arango ArgotyOncology Data Science, Oncology R&D, AstraZeneca, Waltham, MA, USA.
Ioannis KagiampakisOncology Data Science, Oncology R&D, AstraZeneca, South San Francisco, CA, USA.
Mohammad Hassan KhalidAI Accelerators, R&D IT, AstraZeneca, Cambridge, UK.
Etai JacobOncology Data Science, Oncology R&D, AstraZeneca, Waltham, MA, USA.
Krishna C BulusuOncology Data Science, Oncology R&D, AstraZeneca, Cambridge, UK. krishna.bulusu@astrazeneca.com.
Natasha MarkuzonOncology Data Science, Oncology R&D, AstraZeneca, Waltham, MA, USA. natasha.markuzon@astrazeneca.com.ORCID 0009-0007-4926-3871

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate survival prediction for Non-Small Cell Lung Cancer (NSCLC) patients remains a significant challenge for the scientific and clinical community despite decades of advanced analytics. Addressing this challenge not only helps inform the critical aspects of clinical study design and biomarker discovery but also ensures that the 'right patient' receives the 'right treatment'. However, survival prediction is a highly complex task, given the large number of 'omics; and clinical features, as well as the high degree of freedom that drive patient survival. Prior knowledge could play a critical role in uncovering the complexity of a disease and understanding the driving factors affecting a patient's survival. We introduce a methodology for incorporating prior knowledge into machine learning-based models for prediction of patient survival through Knowledge Graphs, demonstrating the advantage of such an approach for NSCLC patients. Using data from patients treated with immuno-oncologic therapies in the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials, we found that the use of knowledge graphs yielded significantly improved hazard ratios, including in the POPLAR cohort, for models based on biomarker tumor mutation burden compared with those based on knowledge graphs. Use of a model-defined mutational 10-gene signature led to significant overall survival differentiation for both trials. We provide parameterized code for incorporating knowledge graphs into survival analyses for use by the wider scientific community.

Indexed as

Biomarkers, TumorCarcinoma, Non-Small-Cell LungLung NeoplasmsMachine LearningSurvival AnalysisClinical Trials as TopicComputer GraphicsHumansKnowledgeMutationPrognosisProportional Hazards ModelsBiomarkers, Tumor

Identifiers

PMID39103897
PMCPMC11302075

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.